Modern Migraine: not just a headache!

Modern Headache Medicine: A Neurovascular and Structural Approach

The medical field now recognizes that a “migraine” is not merely a vascular disorder, but a complex neurological dysfunction involving the brain, autonomic nervous system, neurogenic inflammation, and hyperexcitability of pain processing circuits within the brain.

Migraine patients typically experience core symptoms such as throbbing headache, nausea, vomiting, photophobia, phonophobia, dizziness, or brain fog and mental fatigue. Some individuals may experience premonitory warning signs (Aura), such as flashing lights, numbness, or slurred speech. However, a significant clinical challenge is that many patients do not suffer from migraine alone, but also have underlying structural neck issues contributing to their symptoms.

Overlapping Headache Disorders and Cervicogenic Headache

A substantial number of patients previously diagnosed with migraine who show incomplete improvement with migraine medications alone are often found, upon comprehensive medical history taking and physical examination, to have coexisting headache disorders, including:

• Cervicogenic Headache: Originates from disorders of the cervical joints, neck muscles, or occipital nerves. Patients typically present with chronic neck pain, neck stiffness, occipital pain, pain radiating from the neck up to the head, or pain exacerbated by movements of the neck, upper back, and shoulders.
• Occipital Neuralgia: Inflammation or irritation of the greater or lesser occipital nerves.
• Tension-type Headache / Mixed-type Headache: Headaches resulting from muscle tension or a combination of headache types.

Trigeminocervical Complex: The reason cervical structures can provoke migraine-like headaches is that peripheral cervical nerves and the trigeminal system converge and cross-talk within this deep pain processing center. This explains why patients can take multiple migraine medications yet continue to experience persistent occipital tightness and constant neck pain.

Q&A: The Central Sensitization Concept and Treatment Criteria

Why does pain become increasingly difficult to treat over time?

When the brain is exposed to chronic pain signals over prolonged periods, the central nervous system undergoes Central Sensitization, causing neuronal “hyperexcitability”. Patients develop headaches more readily, at higher frequencies, and with heightened vulnerability to triggers (such as light, sound, emotional stress, or minor sleep schedule disruptions). Global clinical guidelines emphasize “early intervention and prevention” to avoid sustained pain altering neuroplasticity and neural pathways.

How frequent must headaches be to initiate preventive treatment?

• > 4 headache days per month or acute pain medication use frequent enough to impair daily activities: A clinical evaluation for preventive therapy should be initiated.
• > 15 headache days per month (with migraine features on at least 8 days per month over consecutive months): Meets the diagnostic criteria for Chronic Migraine, a state associated with a high risk of Central Sensitization.

Caution: Medication-Overuse Headache (MOH)

Patients who frequently self-medicate with over-the-counter painkillers often become trapped in a vicious cycle where medication worsens the pain, known as Medication-Overuse Headache (MOH). This occurs particularly with frequent consumption of Triptans, NSAIDs, analgesic combinations containing Caffeine, or Opioids. Using Triptans on > 10 days per month over several consecutive months can exacerbate the disease process, trigger rebound headaches, and transform episodic migraine into chronic migraine.

Q&A: Precautions for Triptans and Innovations in CGRP-targeted Therapy

Precautions when using Triptans

Although Triptans provide targeted acute migraine relief, special caution is warranted when co-administering them with agents that increase serotonin levels, such as Duloxetine, Venlafaxine, Amitriptyline, Nortriptyline, Tramadol, and Ondansetron. Concomitant use carries the risk of a severe complication: Serotonin Syndrome (monitor for: palpitations, tremors, diaphoresis, agitation, and high fever; seek emergency medical care immediately if these occur).

A New Era in Migraine Medicine: CGRP-targeted Therapy

Representing a major breakthrough in Precision Migraine Treatment, these agents directly inhibit the neurotransmitter Calcitonin Gene-Related Peptide (CGRP), a key driver in the migraine cascade. This targeted inhibition reduces attack frequency, mitigates neurogenic inflammation (neuroinflammation), and dampens central sensitization. Currently, two primary formulations are available:

• Injectable Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
  
• Oral Gepants: Rimegepant, Ubrogepant, Atogepant
  

Updated recommendations from the Canadian Headache Society place increased emphasis on this class, advising that they can be considered earlier in appropriate candidates without strictly requiring failure of multiple conventional preventive drugs first.

Key Differences Between Botox and CGRP for Migraine Management

• Botox Injections: Primarily act by alleviating surrounding muscle spasm and inhibiting the release of pain mediators from peripheral nerve endings (peripheral sensitization). This approach is well suited for Chronic Migraine patients with concurrent marked cervical and shoulder girdle tension.
• CGRP-targeted Therapy: Directly intercepts pain signaling pathways specific to central trigeminovascular circuits within the brain.

Interventional Pain Procedures and Neuromodulation

For individuals with refractory chronic migraine or mixed headache syndromes unresponsive to pharmacotherapy alone, Interventional Headache Management and electrical neuromodulation technologies offer targeted modalities to recalibrate the pain network:

1. Targeted Interventional Headache Procedures

• Greater Occipital Nerve Block (GON block): Targeted anesthetic infiltration around the greater occipital nerve.
• Supraorbital Nerve Block: Local nerve blockade targeting frontal nerve branches.
• Trigger Point Injections (TPI): Targeted injections addressing hyperirritable taut bands in the cervical, trapezius, and suboccipital musculature.
• Sphenopalatine Ganglion Block (SPG block): Local blockade targeting the deep pterygopalatine fossa ganglion via transnasal delivery.

2. Neuromodulation Technologies

• Vagus Nerve Stimulation (VNS): Utilizes low-intensity electrical currents to stimulate the vagus nerve, reducing neuroinflammation and restoring autonomic nervous system balance. Available modalities include external wearable systems (Non-invasive VNS / Wearable devices) and newer Percutaneous VNS techniques for treatment-refractory presentations.
• Advanced Neuromodulation: For severe, intractable headache disorders (Refractory headache), advanced options may include an implanted Greater Occipital Nerve Stimulator (ONS) or Cervical Spinal Cord Stimulation.

Conclusion

The modern therapeutic paradigm for migraine has shifted away from relying solely on episodic, as-needed analgesics toward individualized, proactive prevention (Precision & Personalized Migraine Care). By reducing headache days, halting progression into chronic migraine, addressing underlying cervical and occipital pathologies, and calming central neuronal hyperexcitability, patients can achieve long-term, sustained quality of life.

Research References

1. Ashina M, et al. Migraine and the trigeminovascular system. Lancet Neurology. 2019.
2. Barmherzig R, Kingston W. Occipital Neuralgia and Cervicogenic Headache. Curr Neurol Neurosci Rep. 2019.
3. Urits I, et al. Minimally Invasive Interventional Therapies for Chronic Migraine. Neurol Ther. 2020.
4. Finnern MT, et al. Cervical Spinal Cord Stimulation for Chronic Headache Disorders. Neuromodulation. 2023.
5. Ariyoshi N, et al. Interventional neuromodulation techniques for cervicogenic headache. 2025.
6. Song D, et al. Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis. Front Neurol. 2023.
7. Yuan H, et al. International Headache Society evidence-based guidelines for non-invasive neuromodulation devices in migraine. Cephalalgia. 2025.
8. Tassorelli C, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology. 2018. American Academy of Neurology.
9. Farahani A, et al. Effects of adding transcutaneous vagus nerve stimulation in vestibular migraine. Sci Rep. 2026. Nature.